They discovered that ketoconazole (KTZ), an FDA-approved antifungal agent, could inhibit exosome biogenesis and secretion via ERK1/2 suppression, thereby enhancing sunitinib therapeutic effect in resistant 786-O RCC cells[125]. The gene discussed is MAPK3; the disease is renal cell adenocarcinoma.